Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Optinose (NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek.

Click here to learn how to join our investigation and obtain additional information or contact us at [e-mail] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Optinose shareholders will receive only up to $14 per share, but this includes the payment of contingent value rights (CVRs) tied to future commercial milestones to achieved by Optinose’s business. Optinose insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Optinose by imposing a significant penalty if Optinose accepts a competing bid. We are investigating the conduct of the Optinose board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.